Trial Search Results
High-Field MRI Iron-Based Contrast-Enhanced Characterization of Multiple Sclerosis and Demyelinating Diseases
Feraheme (ferumoxytol) is FDA-approved for iron supplementation and is composed of iron oxide nanoparticles classified among the ultra-small superparamagnetic iron oxides (USPIO). In this project we hypothesize that Feraheme could become a sensitive and specific marker of active inflammation in multiple sclerosis. We will explore this hypothesis taking advantage of ultra high field strength (7T) MRI to further increase the effectiveness of the contrast agent Feraheme at revealing inflammatory activity.
Stanford is currently not accepting patients for this trial.
- Drug: Feraheme
- Drug: Gadolinium-based contrast
- Patients will be included if they are at least 18 years old and meet the revised
diagnostic criteria for multiple sclerosis, relapsing remitting type.
- Patients will be included based on MR evidence of disease activity after Gadolinium
(enhanced lesion) on a previous screening MR in the previous 3 weeks days before
- Children (age < 18)
- Those who lack decision-making capability
- Contraindication to MRI such as pacemaker, other MR-incompatible metal implants or
- Known allergy to dextran or drugs containing iron salts or any previous history of
severe allergic reactions
- Evidence of iron overload such as hemochromatosis or other hematologic disorders that
imply iron level superior to the normal level.
- Pregnancy or breast feeding.
- History of renal disease or estimated glomerular filtration rate (eGFR) using the
Modification of Diet in Renal Disease (MDRD) <40ml/min/1.73m?
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study